NCT02149758

CompletedPhase 4

EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH ...

Tatyasaheb Kore Dental College Source

Tatyasaheb Kore Dental College

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

sum2141

Study Type

interventional

Actual enrollment (reported)

40

Locations

1 country

Sites

1

Timeline

Study Start

January 2013

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

June 2013

Actual (reported)

Study Completion

June 2013

Actual (reported)

Brief Summary

The hypothesis is that Etoricoxib act as an adjuvant to SRP in alleviating periodontal inflammation by:

1.improving clinical periodontal parameters and,
2.improving the salivary SOD levels.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 40 participants
Study completion date: June 2013
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
January 2013
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
June 2013
Actual (reported)
Study Completion
June 2013
Actual (reported)
First Submitted
May 26, 2014
Actual (reported)
First Posted
May 29, 2014
Actual (reported)

Last Updated: May 29, 2014
Status Verified: May 2014
Last Update Submitted: May 26, 2014

Conditions

Cyclooxygenase Two Inhibitors Etoricoxib Periodontitis Saliva Superoxide Dismutase

Keywords

Cyclooxygenase two inhibitorsEtoricoxibPeriodontitisSuperoxide dismutaseSaliva

Outcome Measures

Primary Outcomes (1)

change from baseline in salivary SOD level
3 months

Study Arms (2)

Etoricoxib

EXPERIMENTAL

Etoricoxib 60 mg once daily

Drug: Etoricoxib

matching placebo

PLACEBO COMPARATOR

matching placebo once daily

Drug: Etoricoxib

Interventions

EtoricoxibDrug

Also known as: Nucoxia, Arcoxia

Etoricoxibmatching placebo

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age30 Years - 60 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Tatyasaheb Kore Dental College
Otherlead

Study Sites (1)

Tatyasaheb kore Dental College And Research Centre

Kolhāpur, Maharashtra, 416137, India

MeSH Terms

Conditions

Periodontitis

Interventions

Etoricoxib

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

SulfonesSulfur CompoundsOrganic ChemicalsPyridinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

Dr.Sumit S. Shetgar, BDS
Tatyasaheb Kore Dental College And Research Centre
PRINCIPAL INVESTIGATOR

Enrollment

40 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 4
Allocation: RANDOMIZED
Masking: QUADRUPLE
Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose: TREATMENT
Intervention Model: FACTORIAL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: BDS (Post graduate student

Study Record Dates

First Submitted

May 26, 2014

First Posted

May 29, 2014

Study Start

January 2013

Date type not reported

This date has not been verified as actual or estimated.

Phase 4

Completed

NCT00935116

Etoricoxib for Postoperative Pain After Thyroid Surgery

Phase 4Unknown

NCT00755521

Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia

Phase 4Unknown

NCT00525993

Efficacy and Safety of Etoricoxib in Acute Ankle Sprain: A Double-Blind Comparative Study Among 2 Treatments Protocols

Phase 4Unknown

NCT00565682

Pain Post Abdominal Laparoscopy Prevention With Arcoxia

Phase 4Completed

NCT00757627

Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)

Phase 4Completed

NCT00752921

Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache

Phase 4Unknown

Primary Completion

June 2013

Actual (reported)

Study Completion

June 2013

Actual (reported)

Last Updated

May 29, 2014

Record last verified: 2014-05

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT02149758
Data provider: ClinicalTrials.gov
Source updated: 2014-05-29
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:19:43 UTC

Locations

IN(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Etoricoxib

matching placebo

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations